Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.110 (a) - (b) (1)  + (1.2.2)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.102 (b)  + (1.2.2)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.3 - Clinical investigation  + (1.2.2)
• Reference:USA 21 CFR Part 320 09-Apr-2025 § 320.22  + (1.2.2)
• Reference:USA Expedited Review: Categories of Research that may be Reviewed Through an Expedited Review Procedure 1998 -  + (1.2.2)
• Reference:USA 21 CFR Part 812 09-Apr-2025 § 812.1  + (1.2.2)
• Reference:USA NIH - Glossary 27-May-2025 Observational study  + (1.2.2)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex A - medical device-001  + (1.2.3)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 2 Paragraph 1 - 3  + (1.2.3)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 2 Paragraph 2 – 3  + (1.2.3)
• Reference:EU ; GBR Regulation (EC) No 178/2002 - Food Safety 01-Jul-2022 Article 2  + (1.2.3)
• Reference:EU ; GBR Regulation (EC) No 1223/2009 - Cosmetic Products 01-Dec-2023 Article 2  + (1.2.3)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 2 Absatz 1 – 2  + (1.2.3)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 2 Absatz 3  + (1.2.3)
• Reference:DEU AMG - Arzneimittelgesetz 19-Jul-2023 § 2 Absatz 3a–4  + (1.2.3)
• Reference:GBR The Medical Devices Regulations 2002 11-Feb-2021 Article 2 in vitro diagnostic medical device  + (1.2.3)
• Reference:GBR The Medical Devices Regulations 2002 11-Feb-2021 Article 2 medical device  + (1.2.3)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3  + (1.2.3)
• Reference:USA 21 CFR Part 50 09-Apr-2025 § 50.3 (k)-001  + (1.2.3)
• Reference:USA 21 CFR Part 56 09-Apr-2025 § 56.104 (d)  + (1.2.3)
• Reference:USA 45 CFR Part 46 09-Apr-2025 § 46.104  + (1.2.3)
• Reference:USA U.S. Code Title 21 30-Sep-2023 § 321 (f)  + (1.2.3)
• Reference:USA U.S. Code Title 21 30-Sep-2023 § 321 (i)  + (1.2.3)
• Reference:USA U.S. Code Title 21 30-Sep-2023 § 321 (h)  + (1.2.3)
• Reference:USA 21 CFR Part 809 06-May-2024 § 809.3 (a)  + (1.2.3)
• Reference:USA FD&C Act - Federal Food, Drug, and Cosmetic Act 30-Sep-2023 Sec 510 (k)  + (1.2.3)
• Reference:USA FD&C Act - Federal Food, Drug, and Cosmetic Act 30-Sep-2023 Sec 512 (f)  + (1.2.3)
• Reference:USA FD&C Act - Federal Food, Drug, and Cosmetic Act 30-Sep-2023 Sec 737 (8)  + (1.2.3)

• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 51  + (1.2.4)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Annex VIII  + (1.2.4)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 47  + (1.2.4)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Annex VIII  + (1.2.4)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 6  + (1.2.4)
• Reference:GBR Directive 93/42/EEC 11-Oct-2007 Article 9  + (1.2.4)
• Reference:USA FD&C Act - Federal Food, Drug, and Cosmetic Act 30-Sep-2023 Section 513  + (1.2.4)

• Reference:ICH ICH E8 Guideline R1 (2021) ANNEX: TYPES OF CLINICAL STUDIES  + (1.2.5)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 Glossary - clinical trial Phases  + (1.2.5)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.21  + (1.2.5)
• Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.85  + (1.2.5)
• Reference:ISO ISO 14155 - Clinical investigation of medical devices for human subjects 2020 Annex I  + (1.2.6)
• Reference:ICH ICH E6 Guideline - Annex 2 R3 Annex 2 Annex 2 3  + (1.2.7)
• Reference:ICH ICH E8 Guideline R1 (2021) -  + (1.2.7)
• Reference:ICH ICH E8 Guideline R1 (2021) 3.3.5  + (1.2.7)
• Reference:ICH ICH E9 Guideline 1998 III  + (1.2.7)
• Reference:WHO WHO - Guidelines for GCP for trials on pharmaceutical products* 1995 9.1  + (1.2.7)
• Reference:WHO WHO - HANDBOOK FOR GOOD CLINICAL RESEARCH PRACTICE (GCP) 2005 Overview of the Clinical Research Process  + (1.2.7)
• Reference:EU Recommendations of the expert group - Risk proportionate approaches in clinical trials 25-Apr-2017 2.  + (1.2.7)
• Reference:EU Recommendations of the expert group - Risk proportionate approaches in clinical trials 25-Apr-2017 4.1  + (1.2.7)
• Reference:EU EMA/298712/2022 - Complex clinical trials – Questions and answers 23-May-2022 -  + (1.2.7)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 62 Paragraph 1  + (1.2.7)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 62 Paragraph 3  + (1.2.7)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 74  + (1.2.7)
• Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 82  + (1.2.7)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 58 Paragraph 1 – 3  + (1.2.7)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 58 Paragraph 5-001  + (1.2.7)
• Reference:EU Regulation (EU) 2017/746 - in vitro diagnostic medical devices 20-Mar-2023 Article 70  + (1.2.7)
• Reference:DEU MPDG - Medizinprodukterecht-Durchführungsgesetz 28-Jun-2022 § 3 Absatz 4  + (1.2.7)